Radioactive 'Seeker' drug targets tough bone cancer in new trial
NCT ID NCT07357519
Summary
This study is testing a new drug called LNTH-2403 for people with osteosarcoma (a type of bone cancer) that has come back or stopped responding to standard chemotherapy. The drug is a specially designed antibody that carries a small amount of radiation directly to cancer cells. The main goals are to find a safe dose and see if the drug can help control the cancer and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED / REFRACTORY OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.